India, Nov. 13 -- Grace Therapeutics, Inc. (GRCE) reported Thursday a wider fiscal second-quarter loss, mainly reflecting the absence of a prior-year warrant valuation gain.
Company Profile
Grace develops treatments for rare diseases. Its lead candidate, GTx-104, is an investigational intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage, bleeding around the brain.
Second-Quarter FY27 Financial Results
For the quarter ended September 30, 2026, net loss widened to $2.13 million, or $0.11 per diluted share, from $0.94 million, or $0.06 per share. The prior-year quarter included a $1.43 million warrant valuation gain, with no comparable gain this year.
The overall loss from operating expenses dropped by 9.4% to $2.29 m...